What's Happening?
Viridian Therapeutics has received FDA approval for Lumvoa, a new treatment for thyroid eye disease (TED), marking the first direct competition to Amgen's Tepezza. Lumvoa, which is approved for both active and chronic stages of TED, offers a faster intravenous
dosing regimen compared to Tepezza. This approval comes as Amgen prepares to introduce a subcutaneous formulation of Tepezza, which could enhance patient convenience. Both drugs function as IGF-1 inhibitors. Viridian plans to launch Lumvoa immediately, pricing it similarly to Tepezza at approximately $150,000 for a six-month course. The company is also developing a subcutaneous version of Lumvoa, expected to be ready for U.S. filing next year. TED is a rare autoimmune disorder causing inflammation and bulging of the eyes, leading to visual disturbances and discomfort.
Why It's Important?
The approval of Lumvoa introduces competition in the TED treatment market, which has been dominated by Tepezza since its approval in 2020. This competition could potentially lead to more treatment options and possibly better pricing for patients. The introduction of a new drug with a different dosing regimen may also improve patient adherence and outcomes. For Viridian, this approval represents a significant milestone as it launches its first commercial product, potentially increasing its market share in the TED treatment space. For Amgen, the competition may prompt further innovation and improvements in their product offerings.
What's Next?
Viridian's immediate launch of Lumvoa and its plans to develop a subcutaneous version indicate a strategic push to capture market share from Amgen. Amgen's upcoming subcutaneous formulation of Tepezza could also influence the market dynamics, offering patients more convenient treatment options. The competition between these two companies may lead to further advancements in TED treatments, benefiting patients with more effective and accessible therapies.
